Cityslicker ... thatt makes sense. And per our conversation:

China: 100,000,000 diabetics (estimated) and growing

India: 85,000,000 diabetics (estimated) and growing

10% with eGFR<60 (estimated)

185,000,000 x 10% = 18,500,000 potential diabetics with eGFR<60

18,500,000 x 25% = 4,625,000 potential diabetics with eGFR<60

Apabetalone cost per patient/annum = $1500.00 (arbitrary estimate)

Therefore:  Rough guesstimate of market potential for China/India combined if P=0.06 is acceptable for diabetics with eGFR<60 for significant RRR:

   >>> Between $6,937,500,000 to $27,750,000,000 in annual sales potentially

For one intial indication, with no Cognitive marketability factored in, that is a VERY fast "ROI" (potentially) for a BP on a $5-10b purchase, or even a $15+ billion purchase potentially ..... with years of patent protection ahead, and the IP (& other molecules?) for further indications and compound development. 

The conversations with BP's must be very interesting.